A Phase 3 interventional study of Inhaled treprostinil solution in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by United Therapeutics. Terminated at 32 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 3, and was the 30th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 3 started in 2018.
This study's enrollment of 41 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
36 studies in Hypertension, Pulmonary by United Therapeutics: 4 open now, 4 under way, 2 of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 36 studies in Hypertension, Pulmonary by United Therapeutics, this one is the 16th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 30th registered.
United Therapeutics’s Hypertension, Pulmonary studies by the year they started, since 1998.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among United Therapeutics’s 36 in Hypertension, Pulmonary:
This tab as a report to print or save as PDF → With an account.
This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).
This is a multi-center, open-label study for eligible participants who completed all scheduled study visits during the Treatment Period of Study RIN-PH-304.
Participants who provide informed consent for this open-label extension study on or prior to the final study visit of RIN-PH-304 may participate in the study, provided all other eligibility criteria are met. The RIN-PH-304 final study visit and the RIN-PH-305 Enrollment Visit will occur on the same day.
All participants will reinitiate inhaled treprostinil at 3 breathes (18 micrograms [mcg]) 4 times daily (QID) during waking hours. Study drug doses should be maximized to tolerability throughout the study, and dose titrations should occur as rapidly as possible (as directed by the Investigator) with a target dosing regimen of 15 breaths QID or the maximum tolerated dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled treprostinil solution (0.6 milligrams per milliliter \[mg/mL\], 6 mcg/breath) QID during waking hours.
Drug: Inhaled treprostinil solution
Inhaled treprostinil solution per dose and schedule specified in the arm
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) can be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent was defined as any AE occurring/worsening at any time after a participant was exposed to study drug up until 7 days after the last dose of study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to 4 years
Change From Baseline to Week 6 in 6-Minute Walk Distance (6MWD)
6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6-minute walk test (6MWT) was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded.
Time frame: Baseline, Week 6
Change From Baseline to Week 6 in Borg Dyspnea Score
The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.
Time frame: Baseline, Week 6
Change From Baseline to Week 6 in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.
Time frame: Baseline, Week 6
| Milestone | Treprostinil |
|---|---|
| Started | 41 |
| Received at least 1 dose of study drug | 41 |
| Completed | 0 |
| Not completed | 41 |
| Withdrew: Death | 8 |
| Withdrew: Study terminated by sponsor | 24 |
| Withdrew: Withdrawal by subject | 9 |
An adverse event (AE) can be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent was defined as any AE occurring/worsening at any time after a participant was exposed to study drug up until 7 days after the last dose of study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Treprostinil |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 35 |
6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6-minute walk test (6MWT) was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded.
| meters | Treprostinil |
|---|---|
| Baseline | 226.5 ± 88.91 |
| Change at Week 6 | 15 ± 43.58 |
The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.
| score on a scale | Treprostinil |
|---|---|
| Baseline | 5.03 ± 2.57 |
| Change at Week 6 | 0.38 ± 1.94 |
The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.
| nanogram/liter (ng/L) | Treprostinil |
|---|---|
| Baseline | 1279.6 ± 2080.19 |
| Change at Week 6 | -155.55 ± 558.96 |
Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treprostinil | 8/41 (19.5%) | 13/41 (31.7%) | 22/41 (53.7%) |
| Event | Treprostinil |
|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 5/41 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/41 |
| Acute myocardial infarctionCardiac disorders | 2/41 |
| Cardiac arrestCardiac disorders | 2/41 |
| Sudden deathGeneral disorders | 2/41 |
| COVID-19 pneumoniaInfections and infestations | 2/41 |
| AnaemiaBlood and lymphatic system disorders | 1/41 |
| Myocardial infarctionCardiac disorders | 1/41 |
| Right ventricular failureCardiac disorders | 1/41 |
| COVID-19Infections and infestations | 1/41 |
| Event | Treprostinil |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 8/41 |
| HeadacheNervous system disorders | 6/41 |
| COVID-19Infections and infestations | 5/41 |
| Back painMusculoskeletal and connective tissue disorders | 4/41 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 4/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/41 |
| AnxietyPsychiatric disorders | 3/41 |
Safety population included all participants who received at least 1 dose of inhaled treprostinil.
| Age, Continuous(years) | Treprostinil |
|---|---|
| Mean | 68.24 ± 7.35 |
| Sex: Female, Male(Participants) | Treprostinil |
|---|---|
| Female | 17 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Treprostinil |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 39 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Treprostinil |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 8 |
| White | 31 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Nov 2022, 47 months.
Results were first posted in Dec 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil